Health care utilization and costs among medicaid-enrolled patients with schizophrenia experiencing multiple psychiatric relapses

Health Outcomes Research in Medicine

Volumn 3, Issue 4, 2012, Pages

  Karve, Sudeep J ^a   Panish, Jessica M ^b   Dirani, Riad G ^b   Candrilli, Sean D ^a  

^a RTI HEALTH SOLUTIONS   (United States)

^b JANSSEN RESEARCH AND DEVELOPMENT   (United States)

Author keywords

Economic burden; Psychiatric relapse; Schizophrenia; Second generation antipsychotics

Indexed keywords

NEUROLEPTIC AGENT;

ADULT; ARTICLE; CHARLSON COMORBIDITY INDEX; COMORBIDITY; FEMALE; FOLLOW UP; HEALTH CARE COST; HEALTH CARE UTILIZATION; HOSPITAL ADMISSION; HOSPITALIZATION COST; HUMAN; ICD-9-CM; MAJOR CLINICAL STUDY; MALE; MEDICAID; MEDICAL CARE; MENTAL HEALTH; OUTPATIENT; PRIORITY JOURNAL; PSYCHOPHARMACOTHERAPY; RELAPSE; RETROSPECTIVE STUDY; SCHIZOPHRENIA; SUBSTANCE ABUSE; TREATMENT DURATION;

EID: 85027933202     PISSN: None     EISSN: 18771319     Source Type: Journal    
DOI: 10.1016/j.ehrm.2012.06.003     Document Type: Article

References (33)

1. National Institute of Mental Health (NIMH). How is schizophrenia treated? 2011. Available at: http://www.nimh.nih.gov/health/publications/schizophrenia/ how-is-schizophrenia-treated.shtml. Accessed February 8,2011.
2. Gerlach J. The continuing problem of extrapyramidal symptoms: strategies for avoidance and effective treatment. J Clin Psychiatry. 1999; 60(Suppl 23): 20-24.
3. Tandon R, Jibson MD. Extrapyramidal side effects of antipsychotic treatment: scope of problem and impact on outcome. Ann Clin Psychiatry. 2002; 14(2):123-129.
4. Ascher-Svanum H, ZhuB, Faries DE, et al. The costofrelapse and the predictors of relapse in the treatment of schizophrenia. BMC Psychiatry. 2010; 10:2.
5. Gilmer TP, Dolder CR, Lacro JP, et al. Adherence to treatment with antipsychotic medication and health care costs among Medicaid beneficiaries with schizophrenia. Am J Psychiatry. 2004; 161(4):692-699.
6. Sun SX, Liu GG, Christensen DB, Fu AZ. Review and analysis of hospitalization costs associated with antipsychotic nonadherence in the treatment of schizophrenia in the United States. Curr Med Res Opin. 2007; 23(10): 2305-2312.
7. Weiden PJ, Olfson M. Cost of relapse in schizophrenia. Schizophr Bull. 1995; 21(3):419-429.
8. Frank RG, Goldman HH, Hogan M. Medicaid and mental health: be careful what you ask for. Health Aff (Millwood). 2003; 22(1):101-113.
9. Thomas MR, Waxmonsky JA, Gabow PA, Flanders-McGinnis G, Socherman R, Rost K. Prevalence of psychiatric disorders and costs of care among adult enrollees in a Medicaid HMO. Psychiatr Serv. 2005; 56(11):1394-1401.
10. Johnson N, Oliff P, Williams E. An update on state budget cuts: at least 46 states have imposed cuts that hurt vulnerable residents and cause job loss. Center on Budget and Policy Priorities. 2011. Available at: http://www.cbpp.org/ cms/index.cfm?fa=view&id=1214. Accessed May 22, 2012.
11. Adamson DM, Chang S, Hansen LG. Health Research Data for the Real World: The MarketScan DatabasesdA White Paper. New York: Thomson Healthcare; 2009.
12. Charlson ME, Pompei P, Ales KL, MacKenzie CR. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis. 1987; 40(5):373-383.
13. Quan H, Sundararajan V, Halfon P, et al. Coding algorithms for defining comorbidities in ICD-9-CM and ICD-10 administrative data. Med Care. 2005; 43(11):1130-1139.
14. Basu A, Manning WG. Issues for the next generation of health care cost analyses. Med Care. 2009; 47(7 Suppl. 1):S109-S114.
15. Fu AZ, Qiu Y, Radican L, Wells BJ. Health care and productivity costs associated with diabetic patients with macrovascular comorbid conditions. Diabetes Care. 2009; 32(12):2187-2192.
16. Wedderburn RWM. Quasi-likelihood functions, generalized linear models, and the Gauss-Newton method. Biometrika. 1974; 61:439-447.
17. Johnson B, Montgomery P. Chronic mentally ill individuals reentering the community after hospitalization. Phase II: the urban experience. J Psychiatr Ment Health Nursing. 1999; 6(6):445-451.
18. Melzer D, Hale AS, Malik SJ, Hogman GA, Wood S. Community care for patients with schizophrenia one year after hospital discharge. BMJ. 1991; 303(6809):1023-1026.
19. Salokangas RK, Saarinen S. Deinstitutionalization and schizophrenia in Finland, I: discharged patients and their care. Schizophr Bull. 1998; 24(3): 457-467.
20. Huff ED. Outpatient utilization patterns and quality outcomes after first acute episode of mental health hospitalization. Is some better than none, and is more service associated with better outcomes? Eval Health Prof. 2000; 23(4):441-456.
21. Olfson M, Marcus SC, Doshi JA. Continuity of care after inpatient discharge of patients with schizophrenia in the Medicaid program: a retrospective longitudinal cohort analysis. J Clin Psychiatry. 2010; 71(7):831-838.
22. Schennach R, Obermeier M, Meyer S, et al. Predictors of relapse in the year after hospital discharge among patients with schizophrenia. Psychiatr Serv. 2012; 63(1):87-90.
23. McDonald M, Hertz RP, Lustik MB, Unger AN. Healthcare spending among community-dwelling adults with schizophrenia. Am J Manag Care. 2005; 11(8 Suppl):S242-S247.
24. Rothbard AB, Lee S, Blank MB. Cost of treating seriously mentally ill persons with HIV following HAART. J Ment Health Policy Econ. 2009; 12:187-194.
25. Law MR, Soumerai SB, Ross-Degnan D, Adams AS. A longitudinal study of medication nonadherence and hospitalization risk in schizophrenia. J Clin Psychiatry. 2008; 69(1):47-53.
26. Svarstad BL, Shireman TI, Sweeney JK. Using drug claims data to assess the relationship of medication adherence with hospitalization and costs. Psychiatr Serv. 2001; 52(6):805-811.
27. Awad AG, Voruganti LN. The burden of schizophrenia on caregivers: a review. Pharmacoeconomics. 2008; 26(2):149-162.
28. Ganguly R, Miller LS, Martin BC. Future employability, a new approach to cost-effectiveness analysis of antipsychotic therapy. Schizophr Res. 2003; 63(1-2):111-119.
29. Wu EQ, Birnbaum HG, Shi L, et al. The economic burden of schizophrenia in the United States in 2002. J Clin Psychiatry. 2005; 66(9):1122-1129.
30. Almond S, Knapp M, Francois C, Toumi M, Brugha T. Relapse in schizophrenia: costs, clinical outcomes and quality of life. Br J Psychiatry. 2004; 184:346-351.
31. Gleeson JF, Alvarez-Jimenez M, Cotton SM, Parker AG, Hetrick S. A systematic review of relapse measurement in randomized controlled trials of relapse prevention in first-episode psychosis. Schizophr Res. 2010; 119(1-3):79-88.
32. Millier A, Sarlon E, Azorin JM, et al. Relapse according to antipsychotic treatment in schizophrenic patients: a propensity-adjusted analysis. BMC Psychiatry. 2011; 11:24.
33. Peuskens J, Trivedi J, Malyarov S, et al. Prevention of schizophrenia relapse with extended release quetiapine fumarate dosed once daily: a randomized, placebo-controlled trial in clinically stable patients. Psychiatry (Edgmont). 2007; 4(11):34-50.